ValuEngine lowered shares of Aduro BioTech (NASDAQ:ADRO) from a sell rating to a strong sell rating in a research report released on Friday, February 2nd.
A number of other research firms also recently weighed in on ADRO. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the stock a buy rating in a research note on Tuesday, October 17th. Oppenheimer started coverage on Aduro BioTech in a research note on Monday, October 30th. They set a buy rating and a $15.00 price target for the company. BidaskClub downgraded Aduro BioTech from a hold rating to a sell rating in a research note on Saturday, December 9th. Finally, Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the stock a buy rating in a research note on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Aduro BioTech currently has an average rating of Buy and an average price target of $17.71.
Shares of Aduro BioTech (NASDAQ ADRO) opened at $6.05 on Friday. The stock has a market capitalization of $483.15, a PE ratio of -4.45 and a beta of 3.01. Aduro BioTech has a one year low of $5.82 and a one year high of $14.05.
In other Aduro BioTech news, COO Gregory W. Schafer sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $9.34, for a total value of $186,800.00. Following the sale, the chief operating officer now owns 155,676 shares of the company’s stock, valued at approximately $1,454,013.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen T. Isaacs sold 7,949 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $7.95, for a total value of $63,194.55. Following the completion of the sale, the insider now directly owns 213,695 shares in the company, valued at approximately $1,698,875.25. The disclosure for this sale can be found here. In the last three months, insiders have sold 172,656 shares of company stock worth $1,486,582. 6.60% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in ADRO. Harvard Management Co. Inc. acquired a new stake in shares of Aduro BioTech during the 3rd quarter worth approximately $69,418,000. JPMorgan Chase & Co. grew its holdings in shares of Aduro BioTech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after purchasing an additional 275,295 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Aduro BioTech during the 4th quarter worth approximately $1,309,000. Baillie Gifford & Co. grew its holdings in shares of Aduro BioTech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after purchasing an additional 130,390 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Aduro BioTech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after purchasing an additional 129,079 shares in the last quarter. 45.13% of the stock is currently owned by institutional investors.
WARNING: This article was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/02/17/valuengine-downgrades-aduro-biotech-adro-to-strong-sell-updated-updated.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.